➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Dow
Baxter
Johnson and Johnson
Boehringer Ingelheim

Last Updated: June 22, 2021

DrugPatentWatch Database Preview

RAPAMUNE Drug Profile


Email this page to a colleague

« Back to Dashboard

When do Rapamune patents expire, and what generic alternatives are available?

Rapamune is a drug marketed by Pf Prism Cv and is included in two NDAs.

The generic ingredient in RAPAMUNE is sirolimus. There are twenty-one drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the sirolimus profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Rapamune

A generic version of RAPAMUNE was approved as sirolimus by ZYDUS PHARMS on January 8th, 2014.

  Try Before You Buy

Drug patent expirations by year for RAPAMUNE
Drug Prices for RAPAMUNE

See drug prices for RAPAMUNE

Recent Clinical Trials for RAPAMUNE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
The Perron InstitutePhase 3
University of Kansas Medical CenterPhase 3
West China HospitalPhase 3

See all RAPAMUNE clinical trials

Paragraph IV (Patent) Challenges for RAPAMUNE
Tradename Dosage Ingredient NDA Submissiondate
RAPAMUNE TABLET;ORAL sirolimus 021110 2010-09-28
RAPAMUNE TABLET;ORAL sirolimus 021110 2010-08-25
RAPAMUNE TABLET;ORAL sirolimus 021110 2009-12-17

US Patents and Regulatory Information for RAPAMUNE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv RAPAMUNE sirolimus SOLUTION;ORAL 021083-001 Sep 15, 1999 AA RX Yes Yes   Try Before You Buy   Try Before You Buy   Try Before You Buy
Pf Prism Cv RAPAMUNE sirolimus TABLET;ORAL 021110-002 Aug 22, 2002 AB RX Yes Yes   Try Before You Buy   Try Before You Buy   Try Before You Buy
Pf Prism Cv RAPAMUNE sirolimus TABLET;ORAL 021110-004 Jan 25, 2010 AB RX Yes No   Try Before You Buy   Try Before You Buy   Try Before You Buy
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for RAPAMUNE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism Cv RAPAMUNE sirolimus SOLUTION;ORAL 021083-001 Sep 15, 1999   Try Before You Buy   Try Before You Buy
Pf Prism Cv RAPAMUNE sirolimus TABLET;ORAL 021110-002 Aug 22, 2002   Try Before You Buy   Try Before You Buy
Pf Prism Cv RAPAMUNE sirolimus TABLET;ORAL 021110-002 Aug 22, 2002   Try Before You Buy   Try Before You Buy
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for RAPAMUNE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0648494 C300055 Netherlands   Try Before You Buy PRODUCT NAME: SIROLIMUS, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT; NATL. REGISTRATION NO/DATE: EU/1/01/171/001 - EU/1/01/171/005 20010313; FIRST REGISTRATION: CH CH/55243 20000926
0763039 18/2008 Austria   Try Before You Buy PRODUCT NAME: TEMSIROLIMUS ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/07/424/001 20071119
0648494 SPC020/2001 Ireland   Try Before You Buy SPC020/2001: 20050808, EXPIRES: 20150925
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Express Scripts
Johnson and Johnson
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.